Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31104122 | 0.78 | WNT1 (0.40) | — | |
| SCHEMBL31103962 | 0.74 | TRPC5 (0.37) | — | |
| SCHEMBL31104089 | 0.74 | TLR9 (0.34) | TLR9TLR8TLR7 | |
| SCHEMBL29497380 | 0.71 | TLR9 (0.38) | TLR9TLR8TLR7 | |
| SCHEMBL31103925 | 0.71 | TLR9 (0.34) | TLR9TLR8TLR7 | |
| SCHEMBL31104339 | 0.68 | TLR9 (0.34) | TLR9TLR8TLR7 | |
| SCHEMBL29497353 | 0.67 | DAO (0.43) | — | |
| SCHEMBL31104417 | 0.67 | TLR9 (0.32) | TLR9TLR8TLR7 | |
| SCHEMBL26631333 | 0.67 | — | — | |
| SCHEMBL31532478 | 0.66 | KDM4E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2024182693-A1 | 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | VIVIDION THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | CHEK1 3342/4885FLT3 186/4885TLR9 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.